1. Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, Kuwayama Y, Mishima HK, Shimizu H, Tomita G, Inoue Y, Kitazawa Y, Tajimi Study Group, Japan Glaucoma Society (2004) The prevalence of primary open-angle glaucoma in Japanese. The Tajimi Study. Ophthalmology 111:1641–1648
2. Collaborative Normal-Tension Glaucoma Study Group (1998) Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 126:487–497
3. Gross RL, Peace JH, Smith SE, Walters TR, Dubiner HB, Weiss MJ, Ochsner KI (2008) Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma 17:217–222
4. Chew PT, RojanaPongpun P, Euswas A, Lu D, Chua J, Hui S, Rait J, Goldberg I, Li B, Travatan CACG Study Group (2006) Intraocular pressure-lowering effect and safety of travoprost 0.04% and latanoprost 0.005% for the treatment of chronic angle closure glaucoma. Asian J Ophthalmol 8:13–19
5. Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA, Travoprost Study Group (2001) Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 132:472–484